Dry powder inhalant capable of preventing mycobacterium tuberculosis from transmitting through respiratory tract

A dry powder inhaler and Mycobacterium tuberculosis technology, applied in the field of medicine, can solve the problems of drug resistance of Mycobacterium tuberculosis, reduce biological activity, tuberculosis disadvantages, etc., achieve the effect of preventing tuberculosis, reducing the number of droplets, and easy production and manufacturing

Inactive Publication Date: 2013-05-22
ZHENGZHOU UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, in order to prevent missed doses and wrong doses in clinical practice, the WHO advocates the use of isoniazid and rifampicin as compound preparations. However, due to the structural problems of the two drugs, isoniazid often causes chemical degradation of rifampicin. Reduce biological activity (Wang Xipei, Wang Siling, etc., Chinese Journal of Pharmacy, 2009), so how to solve the incompatibility of isoniazid and rifampin in the compound preparation of the two is of great significance
[0005] In order to block the transmission of Mycobacterium tuberculosis through the respiratory tract, some scholars made gentamicin, which is difficult to absorb in the lungs, into an aerosol for nasal administration. Kill Mycobacterium tuberculosis in the trachea, bronchi and alveoli (Chad J. Roy et al., Antimicrobial Agents and Chemotherapy, 2010, p. 883–886), but due to the single-drug treatment, it is easy to induce drug resistance of Mycobacterium tuberculosis. Tuberculosis caused by Mycobacterium tuberculosis is obviously disadvantageous
There are also scholars who make capreomycin, which is difficult to absorb in the lungs, into powder aerosols to block the transmission of Mycobacterium tuberculosis through the respiratory tract (Shumaila N. M. Hani et al., Frontiers in Cellular and Infection Microbiol ogy, 2012, 1-11 ), but also derived from the treatment of a single drug, it is easy to induce drug resistance of Mycobacterium tuberculosis, which is obviously unfavorable to tuberculosis caused by Mycobacterium tuberculosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry powder inhalant capable of preventing mycobacterium tuberculosis from transmitting through respiratory tract
  • Dry powder inhalant capable of preventing mycobacterium tuberculosis from transmitting through respiratory tract
  • Dry powder inhalant capable of preventing mycobacterium tuberculosis from transmitting through respiratory tract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] In the specific implementation of the present invention, by weight: 10% of isoniazid sustained-release microspheres, 85.5% of rifampicin sustained-release microspheres, 4.5% of magnesium stearate, the isoniazid sustained-release microspheres are first prepared , rifampicin sustained-release microspheres, and magnesium stearate are mixed together, packed in gelatin, plastic capsules or aluminum-plastic blisters, or packaged in a multi-dose dry powder inhalation device in the form of a reservoir, to obtain. The above-mentioned isoniazid sustained-release microspheres and rifampicin sustained-release microspheres are part of the content of the invention.

Embodiment 2

[0019] In the specific implementation of the present invention, it can also be made by weight: 30% of isoniazid slow-release microspheres, 67% of rifampicin slow-release microspheres, and 3% of stearic acid. , rifampicin sustained-release microspheres, and stearic acid are mixed together, packed in gelatin, plastic capsules or aluminum-plastic blisters, or packed in a multi-dose dry powder inhalation device in the form of a reservoir, to obtain final product. The isoniazid sustained-release microspheres and rifampicin sustained-release microspheres are part of the content of the invention.

Embodiment 3

[0021] In the specific implementation of the present invention, it can also be made by weight: 50% of isoniazid slow-release microspheres, 48% of rifampicin slow-release microspheres, and 2% of magnesium stearate. Spheres, rifampicin sustained-release microspheres, and magnesium stearate are mixed together, packed in gelatin, plastic capsules or aluminum-plastic blisters, or packed in a multi-dose dry powder inhalation device in the form of a reservoir, to obtain, The isoniazid sustained-release microspheres and rifampicin sustained-release microspheres are part of the summary of the invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to a dry powder inhalant capable of preventing mycobacterium tuberculosis from transmitting through respiratory tract, and is capable of effectively solving a medical problem that mycobacterium tuberculosis infects pulmonary tuberculosis through the respiratory tract. The method comprises the following steps of: preparing the dry powder inhalant from 9.9-80% of an isoniazide sustained release microsphere, 19.9-90% of a rifampicin sustained release microsphere and 0.1-5% of a flow aid by weight percent, uniformly mixing the isoniazide sustained release microsphere, the rifampicin sustained release microsphere and the flow aid, packaging in gelatin or plastic capsules or aluminum-plastic bubble caps, or packaging in a multi-dosage dry powder inhalation device in the form of a reservoir, so as to obtain the dry powder inhalant. The dry powder inhalant disclosed by the invention is scientific and rational in formula, easy to produce and manufacture, good in use effect, and favorable for the powder to enter into pulmonary alveoli; the medicine is transmitted to and absorbed by the pulmonary alveoli to effectively kill and inhibit mycobacterium tuberculosis in trachea, bronchia and alveoli secretion of the respiratory tract, so as to reduce the quantity of floating droplets of patients of pulmonary tuberculosis removed in the surrounding environment, and to block the transmission of the mycobacterium tuberculosis in the public environment; and therefore, the dry powder inhalant has an important meaning for preventing the pulmonary tuberculosis.

Description

technical field [0001] The invention relates to medicine, in particular to a dry powder inhaler capable of preventing respiratory transmission of Mycobacterium tuberculosis. Background technique [0002] The transmission routes of tuberculosis include the respiratory tract, digestive tract, skin and uterus, among which the respiratory tract is the main route for mass transmission of Mycobacterium tuberculosis. In 1934, Well proposed that the droplet nuclei (sputum) expelled by the cough of tuberculosis patients contained Mycobacterium tuberculosis, and the droplets could cause tuberculosis infection when they entered the respiratory tract of healthy people. Mycobacterium tuberculosis in droplets (sputum) has a strong ability to survive. In 1969, Loudon's research results showed that 46.7-55.8% of Mycobacterium tuberculosis suspended in the air can still survive after 6 hours and have infection. Ability, when a person sneezes, 10,000 to 40,000 droplets can be sprayed out at ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61K31/4409A61K9/72A61K47/42A61K47/36A61K47/26A61P31/06A61P11/00
Inventor 张正全张振中胡海英刘伟郭新红李寅超范武发曾肖肖
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products